| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $413K | -16.8% | -61.3% |
| SG&A Expense | $904K | -13.9% | -10.8% |
| Net Income | -$1.1M | +26.0% | +44.3% |
| EPS (Basic) | -$1.18 | -1211.1% | -742.9% |
| EPS (Diluted) | -$1.18 | -1211.1% | -742.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.6M | +261.6% | — |
| Short-term Investments | $4.9M | — | — |
| Current Assets | $7.6M | +812.2% | +79.6% |
| Total Assets | $7.6M | +779.1% | +78.9% |
| Current Liabilities | $84K | -71.9% | -87.9% |
| Total Liabilities | $84K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.5M | — | — |
| Financing Cash Flow | $3.3M | — | — |
| -71.9% |
| -87.9% |
| Stockholders' Equity | $7.5M | +1224.8% | +111.2% |